Результаты поиска

[Immunotherapy - The New Era of Oncology].

In the field of immunotherapy, essential progress was achieved over the past years partially demonstrating long lasting therapeutic responses in different tumor entities. A better understanding of the interactions between the tumor and the immune system as well as the integration of immunotherapeutic approaches into clinical routine were the foundations for this development. The different approaches intervene on multiple levels of the immune response and directly or indirectly mount the patient's own immune defense against tumor cells. Immunotherapeutic approaches are represented by cytokine t

Совпадение в полном тексте источника
… Regarding IL21, similar side effects were described, especially fever, chills, liver damage, and effects on the hematopoietic system with neutropenia and thrombocytopenia 127 . Beside leukopenia, interferons may induce vertigo, anorexia, and depression 68 . … Additionally, a high tumor load may lead to an uncontrolled release of cytokines by cytolysis (cytokine release syndrome). mAb acting against tumor antigen may cause fever, chills, respiratory complaints, and rashes. …

Bridging the Gap in Secondary Antibody Deficiencies: Current Evidence and Unmet Needs in Diagnosis and Management with Immunoglobulin Replacement.

Secondary antibody deficiency (SAD) represents a substantial yet under-recognised global healthcare burden. It is more prevalent than primary antibody deficiency, but frequently under-diagnosed and variably managed worldwide. Prompt diagnosis is often hindered by insufficient awareness among clinicians, lack of global consensus on screening/monitoring for SAD among at-risk patients, inadequate clinical immunology services and lack of standardised referral pathways/protocols. Management practices vary widely, with little international agreement, particularly regarding threshold to initiate immu

Совпадение в полном тексте источника
… However, this high serum IgG level could lead to various adverse effects, including headache, myalgia, back pain, arthralgia, fever, chills and flushing, which can occur in more than 40% of patients [ 83 ]. … SCIg, mean dose 0.25 g/kg/month | Baseline: 368 ± 116 After at least 12 weeks of SCIg: 680 ± 171 | Infection rate: 1.01 ± 1.38 (before treatment) → 0.24 ± 0.44 (at least 12 months after SCIg) episodes per patient-year | Local skin rash: 7.6% Infusion site pain: 2.3% Headache: 2.3% Mild nausea: 2.3% Chills …

Multimodal imaging diagnosis of multiple myeloma with renal involvement: a case report.

BackgroundExtramedullary renal involvement secondary to multiple myeloma (MM) is extremely rare and prone to preoperative misdiagnosis. Its clinical and imaging manifestations have not been systematically summarized, leading to frequent preoperative misdiagnosis. To summarize the multimodal imaging characteristics and clinical diagnostic value of MM with renal involvement through a typical case report, so as to improve the understanding and early recognition rate of this disease.Case presentationA 67-year-old male patient with left lumbodorsal pain was examined by multimodal imaging. Ultrasoun

Совпадение в полном тексте источника
… Case presentation Four hospitalization courses and clinical management First hospitalization (March 2-30, 2025, department of urology → hematology) A 67-year-old male was admitted to the Department of Urology in March 2025 with a chief complaint of “dull left lumbar pain for over 1 month” (without chills …

Выборочное ингибирование TLR2 стимулирует созревание олигодендроглиевых клеток потомства до олигодендроцитов.

Важно описать новые технологии для преодоления барьера и поощрения ремиелионации, поскольку многие аксоны остаются демиелиномированными в CNS пациентов с множественным склерозом (MS). Недавние исследования показывают, что LR2 является негативным регулятором созревания олигодендроглиевых клеток потомства (OPC) до олигодендроцитов (OLs) и что TLR2 присутствует в хронических повреждениях MS человека. Однако до недавнего времени не существовало конкретного ингибитора TLR2. Поэтому мы создали пептид, соответствующий TLR2-interacting Домена MyD88 (TIDM), которая конкретно препятствует TLR2, но не др

Понятия, полученные из ОРЭ-МЗ: проницаемость кровеносных барьеров в контексте рецидивов MS и метилпреднизолона.

ОКРУЖАЮЩАЯ СРЕДА: Обнаружение множественных рецидивов склероза (MS) по-прежнему сопряжено с трудностями из-за изменчивости симптомов и смешения факторов, таких, как вспышки и инфекции. Метилпреднизолон (МП) используется для серьезных рецидивов, снижая количество контрастных повреждений на МРТ. Константа притока (Ki), вытекающая из динамического противопоказательного MRI (DCE-MRI), маркера проницаемости кровеносного барьера (BBB), продемонстрировала многообещающее значение в качестве предсказателя активности заболеваний в репродукционных MS (RRMS). ЦЕЛИ: Изучение прогнозируемого значения Ki при

Совпадение в полном тексте источника
… Urinary infections were defined as the presence of fever, chills, dysuria, increased need to void, suprapubic pain, and pathologic urine analysis or positive culture. …

The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead.

Immunotherapy is the upcoming trend in cancer treatment. Traditional cancer treatment methods include surgical resection, radiotherapy, chemotherapy, small molecule targeted drugs, monoclonal antibodies, and hematopoietic stem cell transplantation (HSCT). Surgical resection is useful for early-stage patients but not for metastatic cancer cells; radiotherapy and chemotherapy are more common but produce substantial damage to normal tissues and have poor selectivity. Targeted drugs, including monoclonal antibodies, have better comprehensive efficacy but can also encourage gene mutation of tumor c

Совпадение в полном тексте источника
… The rapid and massive release of cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interferon-γ (IFN-γ) into the bloodstream of patients can lead to fever, chills, hypotension, tachycardia, trouble breathing, and low oxygen. …

LAK to CIK continuum in glioma immunotherapy: a systematic review of efficacy and safety outcomes.

BACKGROUND: Immunotherapy against gliomas, including Glioblastoma multiform (GBM) as the most lethal type combines innate and adaptive immune responses to strengthen systemic and host-specific immunity. Among various cell-based immunotherapies, activated cell therapies utilize autologous immune cells activated ex vivo-such as lymphokine-activated killer (LAK) cells, cytokine-induced killer (CIK) cells, and cytotoxic T lymphocytes. Despite challenges, LAK laid the groundwork for further progress in activated killer cell therapies, such as CIK cells. CIK cells with their MHC-independent lytic ac

Совпадение в полном тексте источника
… Other complications included fever [ 19 , 25 , 29 , 30 , 33 – 35 ], two along with chill [ 13 , 27 ], infection in the location of the reservoir [ 26 , 29 , 31 , 34 ], one case of meningitis and death due to bacterial or fungal infection [ 29 ], drowsiness [ 25 ], confusion [ 30 ], pain and fatigue [ … Kong et al. reported complications of CIK therapy included pyrexia, chills, fatigue, pain, urticaria, erythema, leukopenia, and neutropenia [ 13 ].Han et al. didn’t report specific CIK therapy-related complications [ 18 ].No inflammatory cytokine storm and no severe allergic reaction were reported in …

Infarcts and ischemia in the abdomen: an imaging perspective with an emphasis on cross-sectional imaging findings.

Infarcts and ischemia of abdominal organs may present with acute abdominal pain, and early diagnosis is crucial to prevent morbidity and mortality. Unfortunately, some of these patients present in poor clinical conditions to the emergency department, and imaging specialists are crucial for optimal outcomes. Although the radiological diagnosis of abdominal infarcts is often straightforward, it is vital to use the appropriate imaging modalities and correct imaging techniques for their detection. Additionally, some non-infarct-related abdominal pathologies may mimic infarcts, cause diagnostic con

Совпадение в полном тексте источника
… Twelve days after the embolization, the patient presented to the ER with a high fever, chills, and right upper quadrant pain. An emergent contrast-enhanced abdominal CT showed a large infarcted area in segment 6 (arrows) with air bubbles within this parenchymal segment (arrowheads). … The patient presented to ER with left upper quadrant pain, high fever, and chills 9 days after the embolization procedure. a Axial plane postcontrast abdominal CT showed a large splenic abscess with air–fluid level (arrowhead), which almost completely replaced the splenic parenchyma (arrows). …

Drug Repurposing for the Management of Depression: Where Do We Stand Currently?

A slow rate of new drug discovery and higher costs of new drug development attracted the attention of scientists and physicians for the repurposing and repositioning of old medications. Experimental studies and off-label use of drugs have helped drive data for further studies of approving these medications. A deeper understanding of the pathogenesis of depression encourages novel discoveries through drug repurposing and drug repositioning to treat depression. In addition to reducing neurotransmitters like epinephrine and serotonin, other mechanisms such as inflammation, insufficient blood supp

Совпадение в полном тексте источника
… PMS-Cyproheptadine ® [ 65 ] | Allergic conditions | Potent antihistamine and serotonin antagonist with anticholinergic effects competes with histamine H1 receptors/First, generation histamine H1 antagonist, a piperidine derivative | NA | Extrasystole, hypotension, palpitations, tachycardia, ataxia, chills … mutations in mitochondrial DNA Vorinostat Zolinza ® [ 94 , 95 ] | Cutaneous T-cell lymphoma | Inhibits HDAC enzymes, HCAC1, HDAC2, HDAC3, and HDAC6, which catalyze acetyl group removal from protein lysine residues/Antineoplastic agent, histone deacetylase inhibitor | NA | >10%: peripheral edema, fatigue, chills …

Реальная эффективность, стойкость, терпимость и безопасность атумумаба в клинической практике.

АИСЮ: Описание 12-month :: эффективность, стойкость, терпимость и безопасность атумумаба (ОМБ) -- высокоэффективной терапии для борьбы с заболеваниями (ДМТ) для повторного склероза (МС) в реальном мире. & МЕТОДЫ: Электронные медицинские записи пациентов, начинающих OMB с октября 2020 по август 2022 на two Был проведен обзор комплексных центров НР. Демографические показатели и характеристики болезней и 6- и 12-month Были проанализированы клинические, описанные пациентами и радиоологические показатели. РЕЗУЛЬТАТЫ: Всего 175 пациенты начали ОМБ со средним возрастом 44.9 (СД) 10.4) и продолжительн

Совпадение в полном тексте источника
… First 6 months ( N  = 175) Second 6 months ( N  = 175) Cumulative Interval ( N  = 175) Flu-Like Symptoms 51 (29.1%) 9 (5.1%) 52 (29.7%) Headache 24 (13.7%) 5 (2.9%) 25 (14.3%) Fatigue 15 (8.6%) 4 (2.3%) 17 (9.7%) Chills 12 (6.9%) 0 (0%) 12 (6.9%) Myalgias 10 (5.7%) 0 (0%) 10 (5.7%) Unspecified Flu-like …

Клеточная терапия с мезентичными стволовыми клетками, изготовленными плацентой, для вторичных прогрессивных пациентов с множественным склерозом в а фазы 1 Клинические испытания.

Мезенхимальные стволовые клетки (МСЦ) привлекли значительное внимание к клиническим исследованиям в связи с их иммуномодулятивными свойствами и потенциалом уменьшения воспаления при аутоиммунных расстройствах, таких, как множественный склероз (МС). В настоящем исследовании оценивается безопасность и осуществимость использования МСЦ-В (МСЦ-В) на основе плаценты в five - участники с множественным склерозом второго этапа (СФМ). Основные результаты были сосредоточены на безопасности и терпимости, которые были оценены на основе мониторинга неблагоприятных явлений. six месяцев. Вторичные результаты

Совпадение в полном тексте источника
… To determine the safety of cell injection, early side effects such as fatigue, headache, skin rash, chills, nausea, blood pressure changes, myocardial infarction, respiratory issues, fever during injection, and anaphylactic shock were monitored continuously for 24 h. …

Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma.

IntroductionThis phase 1 trial assessed the safety, pharmacokinetics, and preliminary antitumor activity of RO7297089, an anti-BCMA/CD16a bispecific antibody.MethodsRO7297089 was administered weekly by intravenous infusion to patients with relapsed/refractory multiple myeloma. The starting dose was 60 mg in this dose-escalation study utilizing a modified continual reassessment method with overdose control model.ResultsOverall, 27 patients were treated at doses between 60 and 1850 mg. The maximally administered dose was 1850 mg due to excipients in the formulation that did not allow for higher

Совпадение в полном тексте источника
… Symptoms of IRR in > 1 patient included fever, rigors/chills, and hypertension. Of the 12 patients treated in Arm B (first dose administered over 2 days), there was only 1 with an IRR. No patients experienced an IRR following a new higher dose with intra-patient escalation. …

Advanced Practice Perspectives on Preventing and Managing Tumor Lysis Syndrome and Neutropenia in Chronic Lymphocytic Leukemia.

Tumor lysis syndrome (TLS) and neutropenia are significant toxicities in the treatment of chronic lymphocytic leukemia (CLL). Both TLS and neutropenia can lead to potentially life-threatening complications for patients with chronic lymphocytic leukemia undergoing antineoplastic therapy. This article focuses on diligent risk assessment, prophylaxis, early identification, monitoring, patient education, and prompt intervention for TLS and neutropenia. These are all necessary steps to reduce life-threatening complications. Guidelines are available for risk assessments for both TLS and neutropenia.

Совпадение в полном тексте источника
… Signs and Symptoms As patients with CLL prepare to initiate treatment, it is important that they are aware of signs and symptoms of infection, as well as when to report new or worsening signs and symptoms including fever, chills, sweats, change in cough or new cough, sore throat or new soreness in mouth …

One-year mortality and consequences of COVID-19 in cancer patients: A cohort study.

The 1-year mortality and health consequences of COVID-19 in cancer patients are relatively underexplored. In this multicenter cohort study, 166 COVID-19 patients with cancer were compared with 498 non-cancer COVID-19 patients and 498 non-COVID cancer patients. The 1-year all-cause mortality and hospital mortality rates in Cancer COVID-19 Cohort (30% and 20%) were significantly higher than those in COVID-19 Cohort (9% and 8%, both P < .001) and Cancer Cohort (16% and 2%, both P < 0.001). The 12-month all-cause post-discharge mortality rate in survival discharged Cancer COVID-19 Cohort (8%) was

Совпадение в полном тексте источника
… (3) | 1.000 COPD | 11 (7) | 25 (5) | .429 | 7 (1) | .001 Chronic kidney disease | 3 (2) | 11 (2) | 1.000 | 7 (1) | 1.000 Chronic liver disease | 5 (3) | 7 (1) | .313 | 28 (6) | .18 Arrhythmia | 8 (5) | 18 (4) | .488 | 27 (5) | .764 Symptoms at admission Fever | 118 (71) | 363 (73) | .652 | NA | NA Chills …

Trametinib: a MEK inhibitor for management of metastatic melanoma.

This review presents the current data on the efficacy and safety of the selective mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor trametinib in patients with metastatic BRAF V600-positive melanoma. The pharmacological, safety, and efficacy data come from the Phase I, II, and III studies of trametinib monotherapy, as well as those in combination with the BRAF inhibitor dabrafenib. The most common adverse effects of trametinib therapy are rash, dermatitis, diarrhea, and fatigue. The Phase III METRIC study showed significant improvement in overall survival and progression-

Совпадение в полном тексте источника
… 198 (57) | 199 (95) | 66 (32) | 203 (96) | 72 (34) Pyrexia | 184 (53) | 15 (4) | 73 (21) | 2 (<1) | 107 (51) | 12 (6) | 59 (28) | 4 (2) Nausea | 121 (35) | 1 (<1) | 125 (36) | 2 (<1) | 63 (30) | 0 | 54 (26) | 3 (1) Diarrhea | 112 (32) | 4 (1) | 131 (38) | 1 (<1) | 51 (24) | 1 (<1) | 30 (14) | 2 (<1) Chills …

The Schnitzler syndrome.

The Schnitzler syndrome is a rare and underdiagnosed entity which is considered today as being a paradigm of an acquired/late onset auto-inflammatory disease. It associates a chronic urticarial skin rash, corresponding from the clinico-pathological viewpoint to a neutrophilic urticarial dermatosis, a monoclonal IgM component and at least 2 of the following signs: fever, joint and/or bone pain, enlarged lymph nodes, spleen and/or liver, increased ESR, increased neutrophil count, abnormal bone imaging findings. It is a chronic disease with only one known case of spontaneous remission. Except of

Совпадение в полном тексте источника
… The fever is usually well tolerated and chills are rare. Fatigue is however frequent during the fever flares. In most patients, there is no relation between the fever and the skin rash. …

Preventing osteolytic lesions and osteomyelitis in multiple myeloma.

Multiple myeloma is a hematological malignancy affecting the plasma cells. It is the second most common hematologic cancer in adults. Over 90% of patients develop local osteolytic lesions and skeletal-related events at some point during the progression of the disease. Bone lesions can induce severe pain and immobility and can also increase the risk of fractures and osteomyelitis. Skeletal complications are associated with poor clinical outcomes, affecting quality of life and mortality. Current standards of care for myeloma, e.g., autologous stem-cell transplantation (ASCT) and chemotherapy, do

Complication from Desensitization

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Common side effects of RTX include infusion-related reactions, fever/chills, infection, and respiratory complications. Cardiac Disease Life-threatening cardiac complication is reported but quite rarely. … Within 2 h, he developed infusion-related hypersensitivity reactions consisting of a fever, chill, and nausea, which were resolved by 125 mg methylprednisolone. …

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.

BACKGROUND: Immune thrombocytopenia is an autoimmune bleeding disorder. Daratumumab, a human monoclonal antibody targeting CD38 glycoprotein, is currently under clinical investigation as a potential therapy for autoimmune diseases. This trial aimed to evaluate the efficacy and safety of daratumumab in adults with immune thrombocytopenia. METHODS: This single-center, open-label, phase 2 trial enrolled patients with a platelet count <30 × 109 platelets per L during the screening period. The study protocol comprised a 4-week screening phase, an 8-week treatment course, and a 16-week follow-up pe

Совпадение в полном тексте источника
… Reported symptoms included chills (n = 12 [19%]), elevated blood pressure (n = 10 [16%]), chest tightness or dyspnea (n = 12 [19%]), and nausea (n = 7 [11%]; Supplementary Table S6 ). …

CRS and ICANS: Early detection and personalized management.

T-cell-redirected immunotherapies, including chimeric antigen receptor T-cell therapy and bispecific antibodies, have transformed the treatment of relapsed or refractory hematologic malignancies. However, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) remain the major immune-mediated toxicities that can complicate treatment delivery and contribute to morbidity and non-relapse mortality. CRS is characterized by systemic inflammatory amplification involving activated T cells, tumor cells, monocytes/macrophages, endothelial activation, and cytok

Совпадение в полном тексте источника
… Fever may be accompanied by constitutional symptoms such as chills, myalgia, fatigue, anorexia, and malaise. In mild cases, these symptoms may be self-limiting or respond promptly to antipyretics and supportive care. …